AKRO Quote, Financials, Valuation and Earnings

iBio has a net margin of -- compared to Akero Therapeutics's net margin of -4444.57%. Akero Therapeutics's return on equity of -- beat iBio's return on equity of -148.3%.

Akero Therapeutics has a consensus price target of $50.00, signalling upside risk potential of 70.15%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 52.54%. Given that Akero Therapeutics has higher upside potential than iBio, analysts believe Akero Therapeutics is more attractive than iBio.

Akero Therapeutics has a beta of -0.225, which suggesting that the stock is 122.521% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Akero Therapeutics quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Akero Therapeutics's net income of -$72.7M is lower than iBio's net income of -$4M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -- compared to Akero Therapeutics's net margin of -172.04%. Akero Therapeutics's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -89.04%.

Akero Therapeutics has a consensus price target of $50.00, signalling upside risk potential of 70.15%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 19.99%. Given that Akero Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Akero Therapeutics is more attractive than Madrigal Pharmaceuticals.

Akero Therapeutics has a beta of -0.225, which suggesting that the stock is 122.521% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.418, suggesting its less volatile than the S&P 500 by 141.819%.

Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Akero Therapeutics quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $62.2M. Akero Therapeutics's net income of -$72.7M is higher than Madrigal Pharmaceuticals's net income of -$107M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Akero Therapeutics's net margin of -49.65%. Akero Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Akero Therapeutics has a consensus price target of $50.00, signalling upside risk potential of 70.15%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Akero Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Akero Therapeutics.

Akero Therapeutics has a beta of -0.225, which suggesting that the stock is 122.521% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Akero Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Akero Therapeutics's net income of -$72.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Akero Therapeutics's net margin of -2357.27%. Akero Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Akero Therapeutics has a consensus price target of $50.00, signalling upside risk potential of 70.15%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Akero Therapeutics, analysts believe Palatin Technologies is more attractive than Akero Therapeutics.

Akero Therapeutics has a beta of -0.225, which suggesting that the stock is 122.521% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Akero Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Akero Therapeutics's net income of -$72.7M is lower than Palatin Technologies's net income of -$7.8M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.